Ticagrelor Market, By Strength, By Indication, By Distribution Channel, By Geography

PUBLISHED: July 17, 2026

PAGES: 258 Pages

DELIVERY TIME: 2-3 business days

ADD TO COMPARE

SELECT AN OPTION

Description

Ticagrelor Market is estimated to be valued at USD 2.1 Bn in 2026 and is expected to reach USD 3.3 Bn by 2033, growing at a compound annual growth rate (CAGR) of 7.4% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 2.1 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	7.40%	2033 Value Projection:	USD 3.3 Bn

Ticagrelor, a drug commonly used as a platelet aggregation inhibitor, received approval from U.S. Food and Drug Administration (USFDA) in July 2011 and in the European Union by the European Commission in December, 2010. Ticagrelor is used for the prevention of thrombotic events such as stroke or heart attack in people with acute coronary syndrome or myocardial infarction with ST wave elevation.

Market Dynamics

Rising prevalence of cardiovascular diseases is attributed to rising geriatric population and changing lifestyles. According to World Health Organization (WHO), around 17.9 million people every year die due to cardiovascular diseases (CVDs), which is about 31% of all global deaths. This is expected to positively impact growth of the ticagrelor market over the next decade.

Furthermore, in September 2016, WHO launched the Global Hearts Initiative through which WHO is supporting governments around the world to improve efforts on CVD prevention and control. Thus, increasing number of non-government and government initiatives, in order to aid in prevention of CVD is expected to help in propelling growth of the ticagrelor market over the forecast period.

Key features of the study

It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by the leading players
It profiles leading players in the global ticagrelor market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
Key players covered as a part of this study include C.H. Boehringer Sohn AG & Ko. KG, Pfizer Inc., Eli Lilly and Company, AstraZeneca plc, Natco Pharma Limited, ANHUI HAIKANG PHARMACEUTICAL CO., LTD., Avra Laboratories Pvt Ltd., and Sun Pharmaceutical Industries Ltd
Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
The global ticagrelor market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for ticagrelor market, research and consulting firms, new entrants, and financial analysts

Market Segmentation

By Strength (Revenue, USD Bn, 2021-2033)
60 mg
90 mg
By Indication (Revenue, USD Bn, 2021-2033)
Acute Coronary Syndrome
Ischemic Stroke
By Distribution Channel (Revenue, USD Bn, 2021-2033)
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Region (Revenue, USD Bn, 2021-2033)
North America
- U.S.
- Canada
Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
Middle East
- GCC
- Israel
- Rest of Middle East
Africa
- South Africa
- Central Africa
- North Africa
Key Players
C.H. Boehringer Sohn AG & Ko. KG
Pfizer Inc.
Eli Lilly and Company
AstraZeneca plc
Natco Pharma Limited
Anhui Haikang Pharmaceutical Co., Ltd.
Avra Laboratories Pvt. Ltd.
Sun Pharmaceutical Industries Ltd.

Product Code: CMI2515

1. Research Objective and Assumption

Research Objectives
Assumptions
Abbreviations

2. Market Overview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Strength
- Market Snippet, By Indication
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Market Trends
Key Developments
Pipeline Analysis
Historical Overview
Merger and Acquisition
Regulatory Scenario
PORTER'S Five Forces
PEST Analysis

4. Global Ticagrelor Market, By Strength, 2021-2033, (USD Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
60 mg
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
90 mg
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)

5. Global Ticagrelor Market, By Indication, 2021-2033, (USD Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
Acute Coronary Syndrome
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
Ischemic Stroke
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)

6. Global Ticagrelor Market, By Distribution Channel, 2021-2033, (USD Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)

7. Global Ticagrelor Market, By Regions, 2021-2033, (USD Bn)

Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, By Region, 2022-2033
- Regional Trends
North America
- Market Size and Forecast, By Strength, 2021-2033, (USD Bn)
- Market Size and Forecast, By Indication, 2021-2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021-2033, (USD Bn)
- Market Size and Forecast, By Country, 2021-2033, (USD Bn)
  - U.S.
  - Canada
Europe
- Market Size and Forecast, By Strength, 2021-2033, (USD Bn)
- Market Size and Forecast, By Indication, 2021-2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021-2033, (USD Bn)
- Market Size and Forecast, By Country, 2021-2033, (USD Bn)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Market Size and Forecast, By Strength, 2021-2033, (USD Bn)
- Market Size and Forecast, By Indication, 2021-2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021-2033, (USD Bn)
- Market Size and Forecast, By Country, 2021-2033, (USD Bn)
  - China
  - Japan
  - India
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Latin America
- Market Size and Forecast, By Strength, 2021-2033, (USD Bn)
- Market Size and Forecast, By Indication, 2021-2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021-2033, (USD Bn)
- Market Size and Forecast, By Country, 2021-2033, (USD Bn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Africa
- Market Size and Forecast, By Strength, 2021-2033, (USD Bn)
- Market Size and Forecast, By Indication, 2021-2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021-2033, (USD Bn)
- Market Size and Forecast, By Country, 2021-2033, (USD Bn)
  - North Africa
  - Central Africa
  - South Africa
Middle East
- Market Size and Forecast, By Strength, 2021-2033, (USD Bn)
- Market Size and Forecast, By Indication, 2021-2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021-2033, (USD Bn)
- Market Size and Forecast, By Country, 2021-2033, (USD Bn)
  - GCC Countries
  - Israel
  - Rest of Middle East

8. Competitive Landscape

Heat Map Analysis
Company Profiles
- C.H. Boehringer Sohn AG & Ko. KG
  - Company Overview
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Strategies
- Pfizer Inc.
  - Company Overview
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Strategies
- Eli Lilly and Company
  - Company Overview
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Strategies
- AstraZeneca plc
  - Company Overview
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Strategies
- Natco Pharma Limited
  - Company Overview
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Strategies
- ANHUI HAIKANG PHARMACEUTICAL CO., LTD.
  - Company Overview
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Strategies
- Avra Laboratories Pvt. Ltd.
  - Company Overview
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Strategies
- Sun Pharmaceutical Industries Ltd
  - Company Overview
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Strategies
- Analyst Views